MIR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD

Gut

Volumn 65, Issue 12, 2016, Pages 1938-1950

  He, Chong ^a   Shi, Yan ^a   Wu, Ruijin ^a   Sun, Mingming ^a   Fang, Leilei ^a   Wu, Wei ^a,b   Liu, Changqin ^a   Tang, Maochun ^a   Li, Zhong ^a   Wang, Ping ^a   Cong, Yingzi ^b   Liu, Zhanju ^a  

^a TONGJI UNIVERSITY   (China)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

IBD BASIC RESEARCH; IMMUNOREGULATION; MUCOSAL IMMUNITY

Indexed keywords

INFLIXIMAB; INTERLEUKIN 17; MICRORNA; MICRORNA 301A; NUCLEAR PROTEIN; SNIP1 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN301 MICRORNA, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TH17 CELL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; DISEASE MODEL; IMMUNOLOGY; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; PATHOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

ANIMALS; BIOMARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; IN VITRO TECHNIQUES; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-17; INTESTINAL MUCOSA; MICE; MICRORNAS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940919418     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309389     Document Type: Article

References (46)

1. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 2013;62:1653-64.
2. Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013;62: 1505-10.
3. Sun M, He C, Cong Y, et al. Regulatory immune cells in regulation of intestinal inflammatory response to microbiota. Mucosal Immunol 2015;8:969-78.
4. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. Gut 2014;63:776-84.
5. McLean MH, Dieguez D Jr, Miller LM, et al. Does the microbiota play a role in the pathogenesis of autoimmune diseases? Gut 2015;64:332-41.
6. Ng SC, Tang W, Leong RW, et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut 2015;64:1063-71.
7. Elson CO, Cong Y, Weaver CT, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007;132: 2359-70.
8. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201: 233-40.
9. Langrish CL, McKenzie BS, Wilson NJ, et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004;202:96-105.
10. Kalla R, Ventham NT, Kennedy NA, et al. MicroRNAs: new players in IBD. Gut 2015;64:504-17.
11. Ebert PJ, Jiang S, Xie J, et al. An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a. Nat Immunol 2009;10:1162-9.
12. Lu LF, Boldin MP, Chaudhry A, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 2010;142:914-29.
13. O'Connell RM, Kahn D, Gibson WS, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010;33:607-19.
14. Ponomarev ED, Veremeyko T, Barteneva N, et al. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med 2011;17:64-70.
15. O'Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annu Rev Immunol 2012;30:295-312.
16. Pekow JR, Kwon JH. MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:187-93.
17. Wu F, Zhang S, Dassopoulos T, et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflamm Bowel Dis 2010;16:1729-38.
18. Singh UP, Murphy AE, Enos RT, et al. miR-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses. Immunology 2014;143:478-89.
19. Huang Z, Shi T, Zhou Q, et al. miR-141 regulates colonic leukocytic trafficking by targeting CXCL12beta during murine colitis and human Crohn's disease. Gut 2014;63:1247-57.
20. Wu W, He C, Liu C, et al. miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD. Gut 2015;64:1755-64.
21. Wang M, Li C, Yu B, et al. Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer. J Gastroenterol 2013;48: 1023-33.
22. Lu Z, Li Y, Takwi A, et al. miR-301a as an NF-kappaB activator in pancreatic cancer cells. EMBO J 2011;30:57-67.
23. Mycko MP, Cichalewska M, Machlanska A, et al. MicroRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination. Proc Natl Acad Sci USA 2012;109:E1248-57.
24. Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803.
25. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
26. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996;2:998-1004.
27. Wu W, Sun M, Zhang HP, et al. Prolactin mediates psychological stress-induced dysfunction of regulatory T cells to facilitate intestinal inflammation. Gut 2014;63:1883-92.
28. Yu L, Yang X, Xia L, et al. Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediators Inflamm 2015;2015:793764.
29. Leal RF, Planell N, Kajekar R, et al. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFalpha therapy. Gut 2015;64:233-42.
30. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12.
31. Yang X, Yu L, Yu W, et al. Intestinal wall thickness detected by multidetector spiral computed tomography enterography predicts the disease severity of Crohn's disease. Scand J Gastroenterol 2014;49:807-13.
32. Liu Z, Colpaert S, D'Haens GR, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol 1999;163:4049-57.
33. Ge RT, Mo LH, Wu R, et al. Insulin-like growth factor-1 endues monocytes with immune suppressive ability to inhibit inflammation in the intestine. Sci Rep 2015;5:7735.
34. Feng T, Cao AT, Weaver CT, et al. Interleukin-12 converts Foxp3+ regulatory T cells to interferon-gamma-producing Foxp3+ T cells that inhibit colitis. Gastroenterology 2011;140:2031-43.
35. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-9.
36. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-7.
37. Kim RH, Flanders KC, Birkey Reffey S, et al. SNIP1 inhibits NF-kappa B signaling by competing for its binding to the C/H1 domain of CBP/p300 transcriptional co-activators. J Biol Chem 2001;276:46297-304.
38. Wang H, Flach H, Onizawa M, et al. Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat Immunol 2014;15:393-401.
39. Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 2009;10:1252-9.
40. Murugaiyan G, da Cunha AP, Ajay AK, et al. MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis. J Clin Invest 2015;125:1069-80.
41. Wahlquist C, Jeong D, Rojas-Munoz A, et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014;508:531-5.
42. Law IK, Bakirtzi K, Polytarchou C, et al. Neurotensin-regulated miR-133alpha is involved in proinflammatory signalling in human colonic epithelial cells and in experimental colitis. Gut 2015;64:1095-104.
43. Neurath MF, Weigmann B, Finotto S, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 2002;195:1129-43.
44. Kanagavelu S, Flores C, Termini JM, et al. TIR-domain-containing adapter-inducing interferon-beta (TRIF) regulates Th17-mediated intestinal immunopathology in colitis. Mucosal Immunol 2015;8:296-306.
45. Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006;12:382-8.
46. Guan Q, Ma Y, Hillman CL, et al. Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis. Mol Med 2011;17:646-56.